Cover Image
Market Research Report
Product code 
363125

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2019

Published: | Global Markets Direct | 69 Pages | Delivery time: 1-2 business days

Price

Back to Top
C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2019
Published: November 25, 2019
Global Markets Direct
Content info: 69 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 1, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Respiratory, Cardiovascular, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Breast Cancer, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
  • The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1963TDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development
    • Aristea Therapeutics Inc
    • AstraZeneca Plc
    • ChemoCentryx Inc
    • Dompe Farmaceutici SpA
    • Eli Lilly and Co
    • Merck & Co Inc
    • Pepscan Therapeutics BV
    • Rise Biopharmaceutical Ltd
    • Syntrix Biosystems Inc
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles
    • AZD-5069 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5069 + durvalumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DF-2755A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize CXCR2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ladarixin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3041658 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize CXCR2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • navarixin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-G31P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize CXCR1 and CXCR2 for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reparixin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RIST-4721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR1 and CXCR2 for Solid and Hematological tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-517 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-682 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2019: Aristea Therapeutics announces the completion of enrollment in RIST4721-201, a phase 2a proof-of-concept study of RIST4721 for the treatment of Palmoplantar Pustulosis (PPP)
      • Jun 20, 2019: Syntrix Pharmaceuticals announces dosing of first patient in phase 1/2 clinical trial of SX-682 in Combination with KEYTRUDA (pembrolizumab) in metastatic melanoma
      • May 08, 2019: Aristea Therapeutics appoints Ciara Kennedy, Ph.D. to its board of directors
      • Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors
      • Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer
      • Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
      • Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions
      • Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
      • Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
      • Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
      • Sep 25, 2013: Pharmaceutical company Dompe launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
      • Jul 10, 2013: Dompe announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
      • Dec 06, 2012: Dompe Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
      • Oct 23, 2012: Dompe Announces Enrollment Of First Patient In Phase III Trial On Reparixin
      • Oct 24, 2011: Dompe Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aristea Therapeutics Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by ChemoCentryx Inc, H2 2019
  • Pipeline by Dompe Farmaceutici SpA, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Pepscan Therapeutics BV, H2 2019
  • Pipeline by Rise Biopharmaceutical Ltd, H2 2019
  • Pipeline by Syntrix Biosystems Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019